DSIP
About
About DSIP
Delta Sleep Inducing Peptide (DSIP) is a naturally occurring nonapeptide isolated from rabbit cerebral venous blood during sleep, with reported effects on sleep architecture, stress response, pain modulation, and anti-aging properties. It normalizes sleep patterns without sedation, modulates the HPA axis, and has shown analgesic and adaptogenic properties in research. It is used in optimization medicine for sleep disorders and stress resilience.
Science
Mechanism of Action
Modulates activity of multiple neurotransmitter systems including serotonin, norepinephrine, and GABA; reduces CRH-induced ACTH secretion to dampen HPA axis hyperactivity; may induce delta-wave sleep through direct effects on thalamic and hypothalamic sleep-regulating circuits.
Dosing
Typical Protocol
100–500 mcg subcutaneous injection 30 minutes before sleep; 5–10 day cycles for sleep normalization.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
Find a Verified Provider
See which Vial-verified providers offer DSIP — with trust scores, legal credentials, and pricing transparency.